Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 12, 2019 8:15:36 GMT -5
I believe MC said on Monday that advancing the pipeline molecules through Phase I is not too expensive and they have the money to do so. I don’t remember him saying how many molecules they could fund currently. he’s been saying that ever since TrepT started. It’s very true. The cost for P1 depending on the drug is relatively inexpensive and success in P1 makes it much easier to find partners. He needs to show some results from those comments before I believe he is actually doing it. Mike said on a previous CC (either EPS or INV) they have the funds to bring all pipeline candidates to P1 phase status which takes about 2 years. He mentioned EPI is between Year 1 and 2 and they will be meeting with the FDA to get more guidance. |
|
|
|
Post by peppy on Sept 12, 2019 8:25:09 GMT -5
|
|
|
|
Post by prcgorman2 on Sept 12, 2019 8:49:16 GMT -5
Some success? UTHR is your answer. Is it reasonable to assume it will be the only example?
|
|
|
|
Post by mnholdem on Sept 12, 2019 11:54:42 GMT -5
he’s been saying that ever since TrepT started. It’s very true. The cost for P1 depending on the drug is relatively inexpensive and success in P1 makes it much easier to find partners. He needs to show some results from those comments before I believe he is actually doing it. Mike said on a previous CC (either EPS or INV) they have the funds to bring all pipeline candidates to P1 phase status which takes about 2 years. He mentioned EPI is between Year 1 and 2 and they will be meeting with the FDA to get more guidance. |
|
